Amyvid(florbetapir f 18)
Amyvid (florbetapir f 18) is a small molecule pharmaceutical. Florbetapir f 18 was first approved as Amyvid on 2012-04-06. It has been approved in Europe to treat radionuclide imaging.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
diagnosis | D003933 |
Trade Name
FDA
EMA
Amyvid
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Florbetapir f-18
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AMYVID | Avid Radiopharmaceuticals | N-202008 RX | 2012-04-06 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
amyvid | New Drug Application | 2020-05-26 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
74 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alzheimer disease | D000544 | EFO_0000249 | F03 | 16 | 15 | 5 | 5 | 16 | 53 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | 1 | 1 | 3 |
Postoperative cognitive complications | D000079690 | — | — | — | 1 | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Traumatic brain injuries | D000070642 | S06 | — | 1 | — | — | 2 | 3 | |
Chronic traumatic encephalopathy | D000070627 | — | 2 | — | — | 1 | 3 | ||
Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | 1 | — | — | 1 | 2 |
Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 2 | — | — | — | 2 |
Vascular dementia | D015140 | F01 | 1 | 1 | — | — | — | 1 | |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 1 | — | — | — | 1 |
Frontotemporal dementia | D057180 | G31.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 3 | — | — | — | — | 3 | ||
Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Immunoglobulin light-chain amyloidosis | D000075363 | — | — | — | — | 2 | 2 | ||
Primary progressive aphasia | D018888 | EFO_0009053 | G31.01 | — | — | — | — | 1 | 1 |
Narcolepsy | D009290 | EFO_0000614 | G47.4 | — | — | — | — | 1 | 1 |
Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | FLORBETAPIR F 18 |
INN | florbetapir (18f) |
Description | Florbetapir F-18 is an aromatic ether consisting of a pyridine ring substituted at position 2 by a 2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy group and at position 5 and a 2-(4-methylaminophenyl)vinyl group. A positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease. It has a role as a radioactive imaging agent. It is an organofluorine compound, a member of pyridines, an aromatic ether, a (18)F radiopharmaceutical and a substituted aniline. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CNc1ccc(/C=C/c2ccc(OCCOCCOCC[18F])nc2)cc1 |
Identifiers
PDB | — |
CAS-ID | 956103-76-7 |
RxCUI | 1427224 |
ChEMBL ID | CHEMBL1774461 |
ChEBI ID | 66880 |
PubChem CID | 24822371 |
DrugBank | DB09149 |
UNII ID | 6W15Z5R0RU (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 411 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
73,518 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more